Adjuvant Pembrolizumab in Resected Stage III Melanoma Reply

被引：0
|
作者：
Eggermont, Alexander M. M. [1 ]
Robert, Caroline [1 ]
Suciu, Stefan [2 ]
机构：
[1] Gustave Roussy Canc Campus Grand Paris, Villejuif, France
[2] European Org Res & Treatment Canc Headquarters, Brussels, Belgium
来源：
NEW ENGLAND JOURNAL OF MEDICINE | 2018年 / 379卷 / 06期
关键词：
HIGH-RISK;
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：593 / 595
页数：4
相关论文
共 50 条
  • [41] An audit of PET scan surveillance for stage III and resected stage IV melanoma treated with adjuvant nivolumab in a tertiary centre in Western Australia
    Talbot, Alice A. T.
    Warburton, Lydia
    Lam, Wei-Sen
    ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2021, 17 : 134 - 135
  • [42] Adjuvant ipilimumab for stage III melanoma: the patient voice
    Brundage, Michael
    Hanna, Timothy
    LANCET ONCOLOGY, 2017, 18 (03): : 282 - 284
  • [43] Pembrolizumab increases survival in resected advanced melanoma
    不详
    JOURNAL OF INVESTIGATIVE DERMATOLOGY, 2018, 138 (08) : 1676 - 1676
  • [44] Pembrolizumab Versus Placebo as Adjuvant Therapy in Resected Stage IIB or IIC Melanoma: Final Analysis of Distant Metastasis-Free Survival in the Phase III KEYNOTE-716 Study
    Luke, Jason J.
    Ascierto, Paolo A.
    Khattak, Muhammad A.
    de la Cruz-Merino, Luis
    Del Vecchio, Michele
    Rutkowski, Piotr
    Spagnolo, Francesco
    Mackiewicz, Jacek
    Chiarion-Sileni, Vanna
    Kirkwood, John M.
    Robert, Caroline
    Grob, Jean-Jacques
    de Galitiis, Federica
    Schadendorf, Dirk
    Carlino, Matteo S.
    Wu, Xi Lawrence
    Fukunaga-Kalabis, Mizuho
    Krepler, Clemens
    Eggermont, Alexander M. M.
    Long, Georgina V.
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (14) : 1619 - 1624
  • [45] Adjuvant Radiotherapy for Surgically Resected Stage III Merkel Cell Carcinoma
    Pairawan, Seyed Saeed
    Dominguez, Chloe E.
    Solomon, Naveenraj
    Caba-Molina, David
    O'Leary, Michael
    Reeves, Mark E.
    Namm, Jukes P.
    JAMA SURGERY, 2024, 159 (03) : 347 - 349
  • [46] Cost-Effectiveness Analysis of Adjuvant Therapy for BRAF-Mutant Resected Stage III Melanoma in Medicare Patients
    Saam A. Mojtahed
    Nicole R. Boyer
    Saieesh A. Rao
    Thomas F. Gajewski
    Jennifer Tseng
    Kiran K. Turaga
    Annals of Surgical Oncology, 2021, 28 : 9039 - 9047
  • [47] Cost-Effectiveness Analysis of Adjuvant Therapy for BRAF-Mutant Resected Stage III Melanoma in Medicare Patients
    Mojtahed, Saam A.
    Boyer, Nicole R.
    Rao, Saieesh A.
    Gajewski, Thomas F.
    Tseng, Jennifer
    Turaga, Kiran K.
    ANNALS OF SURGICAL ONCOLOGY, 2021, 28 (13) : 9039 - 9047
  • [48] INCORPORATING POSSIBILITY OF CURE INTO COST UTILITY ANALYSIS FOR NIVOLUMAB IN ADJUVANT TREATMENT OF RESECTED STAGE III/IV MELANOMA IN FRANCE
    Harris, G.
    Orsini, I
    Edmonson-Jones, M.
    Moshyk, A.
    Bregman, B.
    Vanderpuye-Orgle, J.
    Chowdhury, E.
    Gaudin, A. F.
    Kurt, M.
    VALUE IN HEALTH, 2022, 25 (01) : S101 - S101
  • [49] NIVOLUMAB-ADJUVANT THERAPY FOR RESECTED STAGE III-IV MELANOMA: A COST-EFFECTIVENESS ANALYSIS FOR SPAIN
    Presa, M.
    Soria, A.
    Oyaguez, I
    Espinosa, E.
    Echave, M.
    Berrocal, A.
    Manzano, J. L.
    Suarez Rodriguez, J.
    Polanco Sanchez, C.
    VALUE IN HEALTH, 2019, 22 : S457 - S457
  • [50] Effectiveness of pembrolizumab adjuvant compared to placebo in stage 3 melanoma: a systematic review
    Subrata, J. A. K.
    Liauw, R.
    Sutanto, R.
    ANNALS OF ONCOLOGY, 2024, 35 : S1397 - S1397
12345